logo-loader
viewTiziana Life Sciences PLC

Tiziana Life Sciences: Expanding the pipeline, unlocking value

Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) has expanded the range of indications — which include severe inflammatory and autoimmune diseases — of its lead therapy fully human anti-CD3 monoclonal antibody Foralumab, signing a new collaboration in Brazil to develop the nasal formulation of Foralumab to treat respiratory failure in COVID-19 patients. Nasally administered Foralumab would offer a first in class immunotherapeutic approach, designed to strengthen immune defence and to directly address the primary site of inflammation, i.e. the nasal passage and respiratory tract. The acceleration of the demerger and listing plans for the genomics risk assessment business including StemPrintER and SPARE, set for completion in 2020, can help unlock very buoyant commercial prospects, and crystallise the value of both the therapeutic and genomics arms of the business.

Tiziana has expanded the pipeline of indications for the nasal formulation of Foralumab, its fully human anti-CD3 monoclonal antibody (mAb), having signed an agreement to cover collaboration between its team of scientists at the Harvard Medical School and those at the Santa Casa de Misericórdia de Santos hospital in Sao Paulo, to conduct a clinical study to investigate the mAb for treating respiratory failure in COVID-19 patients. The clinical study will include patients, treated either with nasally administered Foralumab alone, or combined with the orally-administered antiviral drug dexamethasone, and is scheduled to start imminently, with clinical data anticipated to be reported by the end of 2020.

 

Quick facts: Tiziana Life Sciences PLC

Price: 142.78 GBX

AIM:TILS
Market: AIM
Market Cap: £276.3 m
Follow

What's in the report?

Financial results and forecasts
Growth drivers
Management
Market conditions
Milestones & inflection points

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

LEGAL NOTICE – IMPORTANT – PLEASE READ:

Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...

FOR OUR FULL DISCLAIMER CLICK HERE

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

Watch

Tiziana Life Sciences: Delivery method & data 'looks promising' ahead of...

Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) has announced plans to begin a clinical study of its nasally administered Foralumab in COVID-19 patients in Brazil. Proactive analyst Emma Ulker talks to Katie Pilbeam about the trial which will begin shortly with clinical data potentially...

on 22/9/20

4 min read